Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern oncology is changing at an unprecedented pace. Immunotherapies, antibody–drug conjugates (ADCs), bispecific antibodies and new targeted therapies are creating treatment opportunities that would have been unimaginable only a few years ago.

Cancer treatment is becoming increasingly personalised and tailored to the biological and molecular characteristics of each tumour, while overall survival is being extended for many people living with cancer.

Yet alongside this remarkable scientific progress, a critical question is emerging:

What does it really mean to live longer after — or with — cancer?

A recent Nature Medicine editorial, entitled “Oncology must confront hidden side effects”, highlights precisely this challenge. While cancer drug development is advancing at remarkable speed, the approaches used to record, assess and manage long-term treatment-related toxicities — and their impact on patients’ quality of life — have not evolved at the same pace.

When a “mild” side effect becomes a major burden

Therapeutic success can create a new reality: people are living longer, but some must also manage treatment-related adverse effects for months, years or even for the rest of their lives.

An adverse event classified clinically as low-grade is not necessarily insignificant to the person experiencing it.

A persistent rash, diarrhoea, stomatitis or other symptoms may substantially affect daily functioning, psychological wellbeing and social life when they continue over long periods.

Similarly, some immune-related adverse events associated with immune checkpoint inhibitors can become chronic, persist for years or even be irreversible.

This highlights an important limitation of the Common Terminology Criteria for Adverse Events (CTCAE), which are widely used to classify and grade treatment-related adverse events.

The duration of adverse events is not adequately reflected, while functional and psychological consequences may also remain outside traditional toxicity assessment.

As a result, what may be considered “manageable” according to conventional clinical criteria can feel very different to the patient living with it every day.

Quality of life cannot be an afterthought

A second important issue is the timing of quality-of-life evidence.

In some cases, quality-of-life findings are reported considerably later than the primary results of a clinical trial, and sometimes after a new drug has already been approved.

This means that patients making treatment decisions during the early years of a new therapy may not yet have a complete picture of how it could affect their daily functioning, emotional wellbeing and overall quality of life.

At the same time, the questionnaires and tools used to assess quality of life need to evolve continuously.

And this cannot happen without the direct involvement of patients themselves.

The experiences and priorities of people receiving treatment should form part of how treatment impact is assessed, rather than being treated as information that is added later.

The example of daraxonrasib

The Nature Medicine editorial highlights the pan-RAS inhibitor daraxonrasib as a telling example. The therapy has shown important survival benefits for patients with aggressive RAS-driven advanced pancreatic cancer, a setting in which treatment options have historically been limited.

At the same time, most patients experienced acneiform rash, with diarrhoea and stomatitis also reported as lower-grade treatment-related adverse events.

Full quality-of-life data — including information on daily functioning and emotional wellbeing — were not yet available because follow-up remained relatively short.

This example illustrates a much wider issue.

If we know that a therapy can significantly extend life, but we do not yet fully understand what that life will be like, an essential part of the information is missing from the conversation between patients and their healthcare teams.

This also has direct implications for informed consent.

Whenever evidence is available, patients need information not only about response rates and survival but also about the potential short- and long-term consequences of treatment for their everyday lives.

The same treatment is not experienced in the same way by everyone

The toxicity profile of a treatment is not identical for every patient.

It may vary according to the drug’s mechanism of action, a person’s physical condition, co-existing long-term conditions, genetic background and other individual characteristics.

Particular attention is needed for populations that have historically been excluded from, or underrepresented in, clinical trials, as their experiences of treatment-related toxicity may differ.

The editorial points, for example, to sex-related differences in adverse events associated with immunotherapy and racial disparities in adverse events observed with CAR-T cell therapy.

This makes real-world data particularly important.

Clinical trials remain fundamental to establishing the safety and efficacy of new treatments. However, broader use in everyday clinical practice may reveal treatment effects that were not fully captured in the populations included in initial studies.

One example is the bispecific antibody amivantamab in lung cancer, where the full extent and severity of some skin toxicities became clearer after a broader patient population was exposed to the treatment.

Moving beyond clinical silos

This changing landscape also demands a different approach to the organisation of cancer care.

The adverse effects of modern cancer therapies do not always fit within a single organ system or medical specialty.

Traditional clinical and disciplinary silos can limit the transfer of knowledge needed to identify, monitor and manage emerging toxicities effectively.

The response therefore needs to be interdisciplinary.

Collaborative networks, updated guidance, systematic reporting, dedicated registries and effective knowledge exchange are increasingly important so that new or rare adverse effects can be recognised early and managed appropriately.

Above all, the patient voice must be heard

Perhaps the most important change concerns how we define treatment success itself.

Survival remains a fundamental goal of oncology.

But it cannot be the only one.

We also need to understand whether people can work, move, sleep, eat, participate in family and social life, maintain as much independence as possible and manage the effects of treatment on their everyday lives.

In other words, we need to know not only how much time a treatment adds to life, but also what that time means to the person living it.

Patients should therefore not enter the process only at the end, as recipients of treatment.

Their perspectives need to be incorporated from the design of clinical trials and assessment tools through to post-approval monitoring and the real-world use of new cancer therapies.

From survival to living after — and with — cancer

Progress in oncology is undeniable, and it brings genuine hope.

The next challenge is to ensure that longer survival is accompanied by quality of life, functioning, meaningful information, participation and dignity.

Modern cancer care therefore needs to move beyond asking only:

“How much longer can this patient live?”

and give equal importance to another question:

“How will this person live during that additional time?”

For Kapa3, this discussion goes to the heart of truly person-centred cancer care: care that sees not only the disease and the treatment, but the person, their everyday life, their needs, their choices and the life that continues during and after cancer.

Source and references

Main source:
Nature Medicine. “Oncology must confront hidden side effects.” Volume 32, July 2026. Published online 8 July 2026. DOI: 10.1038/s41591-026-04554-9.

Barron CC et al. Journal for ImmunoTherapy of Cancer. 2023;11.
Gyawali B et al. Lancet Oncology. 2025;26–e89.
O’Reilly EM et al. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2605555.
Unger JM et al. Journal of Clinical Oncology. 2022;40:1474–1486.
Rayapureddy AK et al. Journal of Clinical Oncology. 2026;44.
Hines MR et al. Transplantation and Cellular Therapy. 2023;29:438.e1–438.e16.

find more s41591-026-04554-9

World Self-Care Day (July 24): The Importance of Self-Care on the Journey with Cancer.

July 24 has been designated as World Self-Care Day. This symbolic date (7/24) was chosen to remind us all of something very basic: that taking care of ourselves is a process that deserves to continue 24 hours a day, 7 days a week.

At the Cancer Patient Support Center, this day takes on a deeper and more meaningful significance. Self-care is not merely a luxury or a passing trend, but a valuable tool for physical, mental, and emotional empowerment—both for patients undergoing treatment and for their caregivers.

What does “self-care” mean?

According to the World Health Organization (WHO), self-care is defined as the ability of individuals, families, and communities to promote health, prevent disease, maintain well-being, and manage illness with or even without the support of a health professional.

This is an active commitment to ourselves, which includes:

1. Healthy daily habits: proper nutrition, adequate sleep, and moderate physical activity (always in consultation with your treating physician)

2. Prevention and responsibility: consistent medication adherence, regular preventive checkups, and following medical instructions.

3. Mental and emotional balance: recognizing personal boundaries, managing stress, accepting our emotions, and seeking help wherever and whenever we need it.

4. Health and health literacy: responsibly staying informed about our health status from reliable sources.

Self-Care in the Cancer Experience

For someone who has experienced cancer, self-care takes on a very personal character. It does not mean that “one must do everything on one’s own.” On the contrary, it is essential to:

• Listen to their body, without feeling guilty about the need for rest

• Take care of their emotional well-being. Allow themselves to feel every emotion—fear, fatigue, but also hope. Psychological support is considered one of the most important acts of self-care.

• Build a support network. It is absolutely essential to allow loved ones or specialized professionals to support them.

Caring for Caregivers

World Self-Care Day is equally dedicated to those who care for patients—family members, partners, and friends. People who stand by patients often tend to neglect their own needs, thereby driving themselves to physical and mental exhaustion. This day serves as a reminder that caring for caregivers is not selfish but an urgent necessity.

For caregivers to practice self-care in practice, they must first set boundaries, as they do not need to bear the entire burden alone. At the same time, it is important for them to acknowledge their emotions without judgment, accepting that fatigue, anger, and frustration are normal reactions. It is equally essential to set aside personal time. Fifteen to thirty minutes a day for a walk or to read a book can be beneficial. Finally, seeking psychological support is not a sign of weakness but an act of self-care.

The Cancer Patient Guidance Center is here for you

At K3, we believe that no one should have to walk this path alone. Self-care is strengthened when there is guidance, reliable information, and human support.

On this special day, let’s all take a step back from the fast pace of life and make our health and well-being a priority.

24 hours a day, 7 days a week: let’s take care of ourselves!

Mapping the efficiency of cancer care in Greece: findings from the All.Can Greece report

Cancer care efficiency in Greece remains one of the most complex and pressing challenges for the Greek health system — not only in terms of its clinical burden, but also in how care is organized around the patient.

With approximately 63,000 new cancer cases diagnosed annually and more than 32,000 cancer-related deaths each year, Greece faces a steadily increasing oncological burden. Projections suggest that cancer incidence will rise by around 23% by 2040, further intensifying pressure on health services.

Against this backdrop, All.Can Greece has published a landmark report titled “Mapping the Efficiency of Cancer Care in Greece”, based on the pilot implementation of the All.Can Action Guide for Efficient Cancer Care.

Rather than simply describing the current situation, the report aims to measure it — identifying where efficiency is lost across the cancer care pathway and where targeted reforms could make the greatest impact.

Cancer care efficiency in Greece: delays in care delivery

One of the most critical findings of the report relates to delays in the patient journey.

Despite the existence of modern infrastructure and highly specialized oncology centres, significant delays persist between initial suspicion, diagnosis, and the start of treatment.

These delays are not the result of a single bottleneck, but of systemic fragmentation:

fragmented referral pathways,
limited coordination between levels of care,
and the absence of standardized clinical protocols.

A key structural weakness is the lack of systematic monitoring of waiting times and time-to-treatment indicators. As a result, inefficiencies remain partially invisible to the system itself, limiting the ability to implement targeted improvements.

Fragmentation across the care continuum

The report highlights a broader issue of fragmentation in cancer care delivery.

The patient journey from primary care to specialist oncology services is often not clearly structured or consistently coordinated. Referral pathways depend heavily on individual practice rather than standardized national protocols.

A major gap is the absence of structured patient navigation services. In practice, this means that patients and families are often left to navigate a complex system on their own, increasing delays and adding unnecessary psychological burden.

At the same time, multidisciplinary tumor boards represent a positive development, supporting collaborative clinical decision-making across specialties. However, systematic monitoring of their performance remains limited.

The development of Comprehensive Cancer Centers is identified as a promising step forward, although further regulatory strengthening and clearer governance structures are still needed to maximize their impact.

Patient-centered care: progress with remaining gaps

Greece has made notable progress in collecting Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs), reflecting a growing commitment to integrating patient perspectives into care delivery.

However, patients’ access to their own clinical data remains limited, restricting their ability to actively participate in decision-making processes.

In addition, patient education and shared decision-making are not yet systematically embedded across the health system.

Another important gap concerns survivorship care. As cancer survival rates improve, the lack of structured long-term follow-up pathways leaves many patients without continuous support after active treatment ends.

Key policy directions

The report outlines several strategic priorities for improving cancer care efficiency in Greece:

Development of a comprehensive national cancer strategy with clear targets and governance mechanisms
Strengthening coordination across all levels of care
Implementation of standardized clinical pathways with defined time-to-treatment and quality indicators
Investment in oncology workforce capacity, particularly in shortage specialties
Establishment of structured patient navigation programmes
Acceleration of Comprehensive Cancer Center development
Systematic use of health data for monitoring performance and accountability
Greater patient engagement through PROMs, PREMs, and shared decision-making

Conclusion: a system with strong foundations but limited integration

Greece has many of the essential building blocks for a high-performing cancer care system — including infrastructure, clinical expertise, and emerging digital health capabilities.

However, the key challenge lies not in the existence of these components, but in their integration.

The All.Can Greece report highlights a system that is still operating in silos: strong individual elements that do not yet function as a fully connected care pathway.

In oncology, this lack of integration is not merely an organizational issue. It directly affects timeliness, patient experience, and ultimately outcomes.

The opportunity now lies in moving from fragmented capacity to coordinated care — where patients no longer have to bridge the gaps between system components themselves.

Source: Mapping-the-Efficiency-of-Cancer-Care-in-Greece-FINAL

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Kapa3 and Karkinaki join forces to support children, adolescents, and families living with cancer

The Cancer Guidance Center – Kapa3 announces its new collaboration with the non-profit organization “Karkinaki”, aiming to strengthen information, psychosocial support, and awareness around childhood and adolescent cancer, as well as to support families experiencing the disease.

Karkinaki is a specialized organization working in the field of childhood and adolescent cancer, focusing on reliable information, empowering parents and caregivers, and fostering a supportive environment around children and teenagers affected by cancer. Through community-based actions and awareness initiatives, it seeks to reduce the sense of isolation that often accompanies diagnosis, while also enhancing understanding, social awareness, and access to available support resources for families.

Within the framework of this collaboration, the two organizations will develop joint initiatives focused on information and awareness-raising, with an emphasis on actions addressing both families and healthcare and support professionals. The partnership will also include the co-organization of informational events, the exchange of good practices, and the exploration of participation in national and European programs that promote a holistic approach to patient care, with an emphasis on continuity of support across all stages of the disease experience.

The Cancer Guidance Center – Kapa3 is dedicated to informing, guiding, and empowering people affected by cancer, providing practical support and access to reliable information and services. At the same time, it develops initiatives that strengthen patients’ active participation in managing their health and promotes a more accessible and human-centered model of care.

In this context, Kapa3 is also involved in European collaborations focusing on the psychosocial dimension of cancer across different stages of life, such as the MELODIC project, which addresses the mental health of young adults with lived experience of cancer. This work further enhances the organization’s ability to recognize needs that emerge throughout the cancer journey, from childhood to adulthood.

This collaboration with Karkinaki reflects the shared vision of both organizations to strengthen a support network that goes beyond medical treatment, extending into families’ daily lives, information access, and psychosocial empowerment, with the aim of providing a more stable and meaningful presence for those who need it most.

Our Press Release here: KARKINAKI PRESS RELEASE

Text: Ifiyenia Anastasiou for Kapa3

Kapa3 and Doctorhomie: Joining Forces to Support Cancer Patients

Kapa3 is pleased to announce the signing of a memorandum of cooperation with the digital home-care platform Doctorhomie. The Kapa3–Doctorhomie collaboration aims to strengthen support for cancer patients and their families across Greece.

Since its establishment, the Cancer Guidance Center – Kapa3 has been actively working to provide meaningful guidance to people living with cancer and their caregivers, with a strong focus on access to benefits and services, information about patients’ rights, and psychosocial support. Through Mobile Units, digital tools and educational initiatives, the organization promotes patient-centred care, creates channels of communication with beneficiaries and strengthens their participation in decisions concerning their health. Kapa3’s philosophy is grounded in building partnerships, leveraging technology and fostering collaborations with organizations that share the same vision.

Doctorhomie, on the other hand, is redefining home-based care in Greece by offering an integrated digital platform that connects patients with physicians, nurses, psychologists, physiotherapists and caregivers. Through tools that enhance monitoring and management of care at home, Doctorhomie contributes to strengthening Primary Health Care, promoting prevention, supporting families and improving both the safety and quality of care.

The new collaboration between Kapa3 and Doctorhomie opens opportunities for joint initiatives at multiple levels, including:

the organization of workshops, conferences and webinars aimed at informing patients, promoting quality of care and strengthening trust between patients and their treating physicians, particularly within the context of home-based care and Primary Health Care,
awareness and information campaigns focusing on prevention, the fight against myths and stigma, and a better understanding of patients’ symptoms and needs,
participation and collaboration in national and European programmes that promote innovation in oncology care and strengthen digital tools for patients and caregivers,
joint research initiatives on topics of shared interest, with the aim of supporting scientific evidence, disseminating knowledge and contributing to health policy development at both national and European level.

This partnership is founded on the shared belief that patient care begins with information and support, is strengthened through education and collaboration, and evolves through the combined use of technology and patient-centred practices.

Kapa3 and Doctorhomie are committed to making the most of this collaboration in order to strengthen patients’ participation in decisions regarding their health, reduce inequalities and provide timely and effective support to those who need it.

With a shared vision of quality and accessible care, Kapa3 and Doctorhomie are opening a new chapter of cooperation in support of cancer patients in Greece.

Download our Press Release in pdf or word

Cancer: From Prevention to Life Coordination – Successful Knowledge Seminar in Megara with Kapa3

With great success and participation from citizens of all ages, the Knowledge Seminar in Megara – From Prevention to Life Coordination took place on Sunday, February 8, in the Council Chamber of the Megara City Hall, in celebration of World Cancer Day.

The event was organized by the Municipality of Megara in collaboration with the Kapa3 Cancer Guidance Center, which since 2020 provides guidance and support to oncology patients and their families, ensuring access to vital information and services.

The seminar opened with a speech by the Mayor of Megara, Panagiotis Margetis, who shared his family’s personal experience with cancer, emphasizing the importance of accurate information and support throughout the patient journey. Stamatis Georgakis, Deputy Mayor for Public Health and Social Protection, coordinated the seminar and highlighted the value of Kapa3 and its Guidance Station in informing, supporting, and advocating for patients’ rights.

Distinguished experts participated in the seminar, presenting key aspects of holistic cancer care:

Georgios Nintos, MD MSc, Oncologist: Prevention and early diagnosis, causes, and preventive measures.
Katerina Papakonstantinou, MD MSc PhD, Obstetrician-Gynecologist: Gynecologic cancer, importance of HPV vaccination and Pap test.
Andrea Paola Rochas, Assistant Professor of Biology, University of Peloponnese Nursing Department: Nutrition and cancer prevention, emphasizing the Mediterranean diet, exercise, and avoidance of processed foods.
Maria Lavdaniti, Professor and Head of Nursing Department, International University: Role of oncology nurses in holistic care.
Pinelopi Vlotinou, Assistant Professor of Occupational Therapy, University of West Attica: Daily living support and quality-of-life improvement through occupational therapy.
Ioanna Sideri, Psychologist MSc, PhD(c), University of Peloponnese: Psychological support for patients and caregivers, resilience, and crisis management.
Grigoria Zacharogianni, MD MSc PhD, Radiation Oncologist: Modern treatment options and importance of moderate exercise during therapy.

The presentation of Kapa3 was delivered by Evangelia Bista, Co-founder and Head of Strategic Partnerships, highlighting the importance of digital literacy and a holistic approach to patient care. Kapa3 has expanded its oncology support network by inaugurating the Cancer Guidance Station in Megara, with the significant support of Megara Resins. In its first year, the station has assisted over 100 beneficiaries, offering guidance on social rights, patient file management, and psychological support, free of charge.

For 2026, Kapa3 is strengthening its digital services with Myrto, Greece’s first AI-powered Health Digital Assistant, providing personalized guidance and voice control. Planned initiatives also include: Wellness in Motion, with 12 outdoor walks for mental wellbeing of young adult cancer patients, the Cancer Wellness Open House Day, and a conference on equitable access to care.

The Knowledge Seminar in Megara – From Prevention to Life Coordination highlighted the importance of prevention, holistic care, interdisciplinary collaboration, digital literacy, psychological support, and continuous patient rights education.

Kapa3 warmly thanks the Municipality of Megara for hosting and supporting the event, as well as all speakers, for their invaluable expertise and commitment to sharing knowledge and scientific know-how.

Explore the photo gallery here:

The Press Release document here